P. Tisovský et al./Chemical Papers 68 (8) 1113–1120 (2014)
Table 1. Physical and spectral data of prepared compounds
1115
Compound
Physical and spectral data
Reference
FTIR (neat), ν˜/cm−1: 3435, 2960, 2933, 2860, 2112, 1728, 1490, 1416, 1380, 1071, This article
961, 890, 802, 757, 728, 690, 651
1
—
H NMR (300 MHz, CDCl3), δ: 9.72 (d, J = 6.4 Hz, 1H, CH O), 7.55–7.51 (m, 2H,
—
HC in Ph), 7.38–7.31 (m, 3H, HC in Ph), 3.61 (td, J = 7.4 Hz, J = 6.4 Hz, 1H, CH),
1.79 (dt, J = 7.4 Hz, J = 7.0 Hz, 2H, CH2), 1.33–1.24 (m, 8H, 4 × CH2), 0.87 (t, J
= 6.9 Hz, 3H, CH3)
13
—
C NMR (75 MHz, CDCl3), δ: 200.7 (C O), 128.5 (CH), 128.3 (CH), 122.7 (CHq
—
IIIa
—
—
in Ph), 89.4 (C—C), 78.6 (C—C), 43.6 (CH), 32.3 (CH2), 31.8 (CH2), 28.4 (CH2),
—
—
25.7 (CH2), 22.7 CH2), 14.1 (CH3)
HRMS, m/z (found/calc.): 229.1590/229.1592 ([M + H]+ , C16H21O)
HPLC (Chiralpak OD-H; IPA/hexane (ϕr = 3 : 97); 1 mL min−1; λ = 254 nm): tR
(major) = 29.13 min, tR (minor) = 35.46 min
FTIR (neat), ν˜/cm−1: 2985, 2143, 1560, 923, 756
Herrmann et al.
1H NMR (300 MHz, CDCl3), δ: 7.56–7.50 (m, 4H, HC in Ph), 7.39–7.29 (m, 6H, HC (2001)
IV
in Ph)
FTIR (neat), ν˜/cm−1: 3318, 3023, 2920, 2855, 2362, 2340, 1596, 1495, 1465, 1379, Joosten et al.
1262, 1029, 964, 801, 738, 691, 669, 617, 492, 419 (2010)
1
—
H NMR (300 MHz, CDCl3), δ: 9.71 (d, J = 7.7 Hz, 1H, (CH O), 7.41–7.20 (m, 5H,
—
—
HC in Ph), 6.61 (d, J = 15.9 Hz, 1H, CH CH), 6.31 (ddd, J = 4.3 Hz, J = 9.0 Hz,
J = 15.9 Hz, 1H, CH CH), 2.73 (m, 1H, CH), 2.39 (dd, J = 7.0 Hz, J = 7.0 Hz, 2H,
—
—
—
CH2), 1.52 (dt, J = 7.3 Hz, J = 6.6 Hz, 2H, CH2), 1.33–1.24 (m, 8H, 4 × CH2), 0.87
(t, J = 6.9 Hz, 3H, CH3)
C NMR (75 MHz, CDCl3), δ: 204.1 (C O), 136.4 (CHq in Ph), 128.5 (C C),
128.6 (CH), 127.9 (CH), 127.8 (CH), 117.4 (C C), 52.8 (CH), 31.8 (CH2), 31.1
VIIa
13
—
—
—
—
—
—
(CH2), 29.3 (CH2), 22.7 (CH2), 14.1 (CH3)
HPLC (Chiralpak AD-H; IPA/hexane (ϕr = 5 : 95); 1 mL min−1; λ = 254 nm): tR
(major) = 17.34 min, tR (minor) = 20.18 min
FTIR (neat), ν˜/cm−1: 3442, 2932, 2870, 1732, 1456, 1442, 1410, 1250, 1061, 930, 720, Joosten et al.
692, 537 (2010)
1
—
H NMR (300 MHz, CDCl3), δ: 9.70 (d, J = 7.3 Hz Hz, 1H, CH O), 5.63 (ddt, J
—
—
—
—
= 17.1 Hz, J = 10.5 Hz, J = 7.4 Hz, 1H, CH CH2), 4.85–4.75 (m, 2H, CH CH2),
—
2.69 (tdt, J = 7.3 Hz, J = 7.3 Hz, J = 7.0 Hz, 1H, CH), 2.41 (dd, J = 7.4 Hz, J =
7.0 Hz, 2H, CH2), 1.51 (dt, J = 7.3 Hz, J = 6.6 Hz, 2H, CH2), 1.41–1.28 (m, 8H,
4 × CH2),0.86 (t, J = 7.0 Hz, 3H, CH3)
VIIb
13
—
—
—
—
C NMR (75 MHz, CDCl3), δ: 204.5 (C O), 135.7 (C C), 115.7 (C C), 52.5
—
—
(CH), 31.8 (CH2), 31.7 (CH2), 29.3 (CH2), 27.8 (CH2), 22.7 (CH2), 14.3 (CH3)
HPLC (Chiralpak OD-H; IPA/hexane (ϕr = 5 : 95); 1 mL min−1; λ = 216 nm): tR
(major) = 26.54 min, tR (minor) = 31.27 min
FTIR (neat), ν˜/cm−1: 3442, 2965, 2932, 2870, 1732, 1456, 1220, 1170, 1061, 720, 503 Kato et al. (1997)
1
—
H NMR (300 MHz, CDCl3), δ: 9.71 (d, J = 7.2 Hz, 1H, CH O), 2.57 (dqd, J =
—
7.8 Hz, J = 6.2 Hz, J = 4.8 Hz, 1H, CH), 1.68–1.54 (m, 4H, 2 × CH2), 1.33–1.27 (m,
16H, 8 × CH2), 0.88 (t, J = 5.8 Hz, 6H, 2 × CH3)
13
—
C NMR (75 MHz, CDCl3), δ: 204.3 (C O), 50.9 (CH), 31.8 (CH2), 28.8 (CH2),
—
26.9 (CH2), 22.7 (CH2), 14.2 (CH3)
GC (Lipodex E, γ-cyclodextrin, 100◦C, 122 kPa): tR (major) = 12.5 min, tR (minor)
= 13.7 min
VIIc
VIId
FTIR (neat), ν˜/cm−1: 3027, 2960, 2922, 2854, 2360, 2342, 1723, 1685, 1600, 1496, Afewerki et al.
1452, 1260, 1074, 1014, 963, 794, 737, 693, 670, 493
(2012)
1
—
H NMR (300 MHz, CDCl3), δ: 9.76 (d, J = 1.8, 1H, CH O), 7.46–7.21 (m, 10H,
—
—
HC in Ph), 6.61 (d, J = 15.9 Hz, 1H, CH CHPh), 6.31 (ddd, J = 4.3 Hz, J = 9.0 Hz,
J = 15.9 Hz, 1H, CH CHPh), 2.87 (d, J = 7.4 Hz, 2H, CH2), 2.84 (tdt, J = 7.4 Hz,
—
—
—
J = 7.4 Hz, J = 7.1 Hz, 1H, CH), 2.43 (dd, J =7.1 Hz, J = 7.0 Hz, 2H, CH2)
13
—
C NMR (75 MHz, CDCl3), δ: 202.3 (C O), 138.0 (CHq in Ph), 136.4 (CHq in Ph),
—
—
128.8 (C C), 128.6 (CH), 128.5 (CH), 128.1 (CH), 127.9 (CH), 126.1 (CH), 114.8
—
—
(C C), 54.9 (CH), 34.7 (CH2), 30.7 (CH2)
—
HPLC (Chiralpak AS-H; IPA/hexane (ϕr = 3 : 97); 0.5 mL min−1; λ = 254 nm): tR
(major) = 32.19 min, tR (minor) = 43.74 min